Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT02393378
Treatments Against RA and Effect on FDG-PET/CT
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT02374021
- Locations
- 🇺🇸
IRIS Research and Development, Plantation, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 369
- Registration Number
- NCT02332590
- Locations
- 🇺🇸
Investigational Site Number 840403, Saint Petersburg, Florida, United States
🇺🇸Investigational Site Number 840229, Coral Gables, Florida, United States
🇺🇸Investigational Site Number 840140, Tampa, Florida, United States
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 201
- Registration Number
- NCT02333383
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02330380
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Schneider Children's Medical Center, Israel
- Target Recruit Count
- 82
- Registration Number
- NCT02256462
- Locations
- 🇮🇱
Schneider Children's Hospital, Petach Tikva, Israel
Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Brugmann University Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT02252809
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 992
- Registration Number
- NCT02207244
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 837
- Registration Number
- NCT02207231
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT02196701
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.